The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
18 pts

Opinion on  Nabi Biopharmaceuticals (NABI)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
Shorts will be squeezed?

Aug 23, 2007 09:34 PM GMT
Lee2004_11_26
Return Risk
-7.34% HIGH
Sr. Associate

Nabi   is a heavily shorted stock,  which has a short ratio of 21 and 14% of the float shorted. Nabi makes and sells products to help with transplantation, infectious disease, nicotine addiction and hematology. The stock has negative earnings and a P/S of 2. The stock happens to be owned by the Los Angeles-based activist hedge fund, Chapman Capital , run by Bob Chapman. His hedge fund, which he ran on the side for a couple years, had a net return of 55% in 2004 and 61.9% in 2005. Nabi is also owned by Third Point LLC , another activist hedge fund founded by Daniel Loeb. The fund has had an average annual return of 28.9% since 1995. Two conferences are on the way in September and the company is selling its divisional assets.  IMHO, probably the shorts will get squeezed soon.


Update 08/23:

Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Thursday August 23, 4:45 pm ET

 

BOCA RATON, Fla., Aug. 23 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI - News ) today announced that Dr. Leslie Hudson, interim president and chief executive officer will participate in the Thomas Weisel Partners Healthcare Conference, to be held Sept. 5-7, 2007 at The Four Seasons Hotel in Boston. Dr. Hudson's presentation at the conference is scheduled for Thursday, Sept. 6 at 2:05 p.m. EDT. Dr. Hudson is also scheduled to participate in the Bear Stearns Healthcare Conference, to be held Sept. 10-11, 2007 at The Grand Hyatt Hotel in New York, where he is slated to present on Tuesday, Sept. 11 at 2:30 p.m. EDT.


Update 09/06:

Nabi Biopharmaceuticals said Wednesday that nine-month data from its ongoing trial showed continued positive results for developmental vaccine NicVAX, which is used to treat nicotine addiction.  The trial enrolled 301 heavy smokers who smoked an average of 24 cigarettes per day before enrollment.

Today's volume is above the average and the price was up more than 9%. IMHO, the upcoming 2 industrial conference will make this heavy shorted baby smoking and flaming.


NABI:  This call was made on 08/23/07 @ $3.67
Rating:   Positive   $3.67 (08/23/07)
Gain/Loss:   -55.59% in 1740 days
Target:   $5.50 (+49.86%) in Three months


Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 21.10 +34.36% 531
2 18.14 +36.28% 286
3 17.66 +23.07% 83
4 13.47 +13.37% 69
5 12.13 +132.16% 102


POPULAR STOCKS
Symbol Company Name Sentiment

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
Nabi Biopharmaceuticals (NABI)
   SocialPicks Sentiment:   

   This Quarter's Sentiment:
All:
77.5%
Top:
100.0%




Latest Picks by Moneycrackerlee
Symbol SP Sentiment Rating Return Since
FXP Negative +76.17% 09/18/08
JASO Positive -94.45% 08/29/08
WFR Positive -96.78% 08/22/08
NOK Positive -88.72% 08/22/08
JCP Positive -28.81% 08/22/08

View All >
   




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch